Cannabis Indica in Victorian Medicine
Cannabis as a legitimate Victorian therapeutic agent: fifty years of clinical use and gradual decline.
Victorian doctors genuinely prescribed cannabis resin and tinctures for real ailments—migraine, neuralgia, tetanus spasms. But they abandoned it not because of conspiracy, but because aspirin, morphine, and barbiturates worked more reliably and were easier to dose. The later moral panic that criminalized cannabis (1920s–30s) happened after medicine had already moved on.
Cannabis enters European medicine: from Asia to Britain
Hemp had been grown in Britain for fibre and seeds since the Tudor period, appearing in early herbals as a remedy for coughs and mild complaints. The psychoactive Indian variety—Cannabis indica as formally named by Lamarck in 1785—remained largely unknown to British physicians until the 1830s. Weak / limited[1]
European knowledge of cannabis intoxication came first through colonial and traveller accounts of bhang, ganja, and charas in India, and hashish in Egypt and Syria. French military and medical observers encountered hashish during the Egyptian campaigns (1798–1801), and French alienists including Jacques-Joseph Moreau began experimental use around the 1840s as a model for studying psychotic states. Weak / limited[2]
Britain's entry point was different: cannabis entered Western medicine as a colonial Indian drug, brought home by military physicians and pharmacologists.
O'Shaughnessy's 1839 paper and the birth of Western cannabis medicine
William Brooke O'Shaughnessy, an Irish physician at the Medical College of Calcutta, published On the Preparations of the Indian Hemp, or Gunjah in the Provincial Medical Journal in 1839—the founding document of cannabis in Western medicine. Strong evidence[3]
O'Shaughnessy reviewed Indian and Persian medical uses, performed dose-finding trials on animals, and then administered cannabis tincture and resin to patients with rheumatism, cholera, tetanus, hydrophobia (rabies), and infantile convulsions. His most striking results came from tetanus and infant convulsions: he reported dramatic relief of spasms and violent muscular contractions. These cases persuaded British physicians to take the drug seriously despite the scarcity of experimental controls by modern standards. Strong evidence[3]
O'Shaughnessy returned to Britain in the early 1840s with samples. By 1843, commercial preparations were being sold by the Oxford Street pharmacist Peter Squire as Squire's Extract, a cannabis resin product that remained in use for decades. Weak / limited[4]
What Victorian physicians prescribed cannabis for
Between roughly 1840 and 1890, cannabis appeared in British and American medical journals as a treatment for specific conditions. The best-documented uses in the period's own literature were:
Migraine and neuralgia. John Russell Reynolds, a physician to Queen Victoria's household, wrote in The Lancet in 1890 that 'Indian hemp, when pure and administered carefully, is one of the most valuable medicines we possess'—specifically for migraine, neuralgia, and senile insomnia. He reported using it clinically for thirty years. Strong evidence[5]
Dysmenorrhoea (menstrual pain). Reynolds and other physicians recommended cannabis tincture for period pain. This clinical recommendation has been conflated with a persistent online claim that Queen Victoria herself was prescribed cannabis for cramps. Disputed Reynolds was indeed her physician and did advocate for cannabis in dysmenorrhoea as a general principle, but no surviving prescription, court record, or personal account confirms she personally received it. Weak / limited[6]
Tetanus and convulsive disorders. Following O'Shaughnessy's dramatic case reports, cannabis was tried for tetanus spasms and infantile convulsions, though results were inconsistent once clinical use widened. Weak / limited[3]
Insomnia and alcohol withdrawal. Cannabis tincture was prescribed for insomnia and 'delirium tremens', especially in cases where other remedies had failed.
Asthma. Cannabis was smoked as part of compound 'asthma cigarettes', though stramonium (datura) was more widely used and preferred. Weak / limited[1]
Cannabis was also tried with poor or no results for rabies, cholera, and terminal cancer pain. Weak / limited[1][3]
Preparations, potency, and the standardisation problem
The standard Victorian preparations were Tinctura Cannabis Indicae (an alcoholic extract of cannabis resin), Extractum Cannabis (a semi-solid resinous extract), and occasionally crude resin itself. The British Pharmacopoeia of 1867 listed doses for tincture ranging from a few minims upward, with physicians titrating against observed effect. Strong evidence[7]
The fatal practical problem—fatal to cannabis's clinical career—was potency variation. Resin shipments from different regions and harvest years contained wildly different amounts of active cannabinoids. Without any method to assay THC (which was not chemically identified until 1964 Strong evidence[8]), physicians could not predict whether a given dose would be subtherapeutic, effective, or produce frank intoxication and anxiety. This unpredictability made cannabis unreliable as a mainstream therapeutic agent.
The Indian Hemp Drugs Commission Report of 1894—a comprehensive 3,000-page British colonial inquiry into cannabis use in India—documented this variability extensively and concluded that moderate use was generally not harmful, but that for medical dosing, the drug was 'too uncertain and varying in strength.' Strong evidence[9]
The decline of cannabis in medicine, 1890–1930
Cannabis did not disappear from Victorian and Edwardian medicine because of moral panic or anti-drug campaigns. It declined for straightforward pharmacological reasons:
Aspirin (1899). Acetylsalicylic acid provided reliable, predictable analgesia and anti-inflammatory action for headache and neuralgia—cannabis's strongest indications—without the dosing uncertainty. Weak / limited[1]
Injectable morphine and barbiturates (from 1903). These offered titratable, dependable sedation and analgesia. Cannabis, being lipophilic and poorly absorbed by oral route, could not compete for systemic pain or sedation control in clinical practice. Weak / limited[1]
Synthetic hypnotics. Chloral hydrate (1869) and paraldehyde offered predictable sleep induction for insomnia, displacing cannabis-based remedies. Weak / limited[1]
By the 1920s–1930s, when international prohibition campaigns began (notably the 1925 Geneva Convention Strong evidence[10]), cannabis was already marginal in therapeutics. It remained listed in the British Pharmacopoeia until 1932 and the US Pharmacopeia until 1942, but as a legacy entry rather than an actively prescribed drug. Weak / limited[1]
Myths and what the historical record actually shows
Several popular claims about Victorian cannabis deserve correction:
'Queen Victoria was prescribed cannabis for menstrual cramps and smoked it.' Disputed Victoria almost certainly did not smoke cannabis. The claim that she received cannabis tincture from her physician John Russell Reynolds rests on inference: Reynolds did recommend cannabis for dysmenorrhoea in general, and he was her doctor, but no surviving prescription, diary entry, or court record documents her personal receipt of it. The claim is repeated widely online but traces to speculation rather than documentary evidence. Weak / limited[6]
'Victorian cannabis preparations were the same as modern cannabis flower.' No data Victorian physicians used whole-plant resin extracts and tinctures of unknown and variable cannabinoid ratios, often degraded by months at sea and storage in warm climates. Modern high-THC cannabis flower is not a like-for-like historical comparison.
'Cannabis was a wonder drug suppressed by pharmaceutical industry.' Anecdote Cannabis was displaced by drugs that simply worked more reliably and predictably for the same indications. The later prohibition of cannabis (1920s–1930s) is a real and separate historical event, driven by racist drug enforcement in America and international treaty-making, but it came after medicine had already largely moved on from cannabis therapeutics for practical reasons.
Sources
- Book Mills, J. H. (2003). Cannabis Britannica: Empire, Trade, and Prohibition 1800–1928. Oxford University Press.
- Book Moreau, J.-J. (1845). Du Hachisch et de l'Aliénation Mentale: Études Psychologiques. Paris: Fortin, Masson.
- Peer-reviewed O'Shaughnessy, W. B. (1843). On the Preparations of the Indian Hemp, or Gunjah. Provincial Medical Journal and Retrospect of the Medical Sciences, 5(123), 363–369.
- Book Booth, M. (2003). Cannabis: A History. Doubleday.
- Peer-reviewed Reynolds, J. R. (1890). Therapeutical uses and toxic effects of Cannabis indica. The Lancet, 135(3473), 637–638.
- Reported Crawford, V. (2002). A homelie herbe: Medicinal cannabis in early England. Journal of Cannabis Therapeutics, 2(2), 71–79.
- Government General Council of Medical Education and Registration (1867). British Pharmacopoeia. London: Spottiswoode.
- Peer-reviewed Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society, 86(8), 1646–1647.
- Government Indian Hemp Drugs Commission (1894). Report of the Indian Hemp Drugs Commission, 1893–94. Simla: Government Central Printing Office.
- Government League of Nations (1925). International Opium Convention, Geneva, 19 February 1925.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- 1961 Single Convention on Narcotic Drugs — The UN treaty that unified international drug control and shaped cannabis prohibition glob...
- Cannabis in Ayurvedic Medicine — Cannabis entered formal Ayurveda around the 8th century CE; earlier Vedic references remai...
- UN Drug Treaties and Cannabis — Three UN treaties control cannabis globally; legalization exists despite treaty language f...